A PYMNTS Company

US: AstraZeneca makes history in pay-for-delay win

By  |  December 7, 2014

UK pharmaceutical conglomerate AstraZeneca secured a landmark ruling last Friday when a jury in federal court found the firm did not harm competition through a pay-for-delay scheme with India-based generics firm Ranbaxy.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, while the jury found that AstraZeneca had made unjustified payments to Ranbaxy to delay the release of a generic form of a competitive drug, the jury said those payments were not unreasonably anticompetitive because no competing company had the regulatory clearance to sell that generic drug.

    The case was the first pay-for-delay suit since the US Supreme Court sided with the Federal Trade Commission in ruling that such agreements could be deemed anticompetitive.

    Dozens of drugstore chains, wholesalers and potentially hundreds of thousands of class members had sued AstraZeneca for violating antitrust law when it paid Ranbaxy to delay the release of the generic, cheaper form of Nexium. AstraZeneca reportedly faced up to $10 billion in fines.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.